Cargando…

Combination of IFN-α/Gm-CSF as a Maintenance Therapy for Multiple Myeloma Patients After Autologous Stem Cell Transplantation (ASCT): A Prospective Phase II Study

Interferon alpha (IFN-α) has been used as a maintenance therapy after autologous stem cell transplantation (ASCT) for multiple myeloma (MM) patients. In this study, we combined GM-CSF with IFN-α in order to improve IFN tolerance in post-ASCT myeloma patients. Primary aims were to evaluate myelotoxic...

Descripción completa

Detalles Bibliográficos
Autores principales:	Salmasinia, Donya, Chang, Myron, Wingard, John R., Hou, Wei, Moreb, Jan S.
Formato:	Texto
Lenguaje:	English
Publicado:	Libertas Academica 2010
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2999958/ https://www.ncbi.nlm.nih.gov/pubmed/21151584 http://dx.doi.org/10.4137/CMO.S6161

Ejemplares similares

Long-Term Outcome after Autologous Stem Cell Transplantation with Adequate Peripheral Blood Stem Cell Mobilization Using Plerixafor and G-CSF in Poor Mobilizer Lymphoma and Myeloma Patients
por: Moreb, Jan S., et al.
Publicado: (2011)

Tandem Autologous Stem Cell Transplantation for Multiple Myeloma Patients Based on Response to Their First Transplant—A Prospective Phase II Study
por: Byrne, Michael, et al.
Publicado: (2014)

Post-Autologous (ASCT) Stem Cell Transplant Therapy in Multiple Myeloma
por: Al-Mansour, Zeina, et al.
Publicado: (2014)

COVID 19 Infection in Autologous Stem Cell Transplant (ASCT) Recipients: a Single Institution Observational Cohort
por: Moreb, Jan S., et al.
Publicado: (2023)

Induction therapy prior to autologous stem cell transplantation (ASCT) in newly diagnosed multiple myeloma: an update
por: Bazarbachi, Abdul Hamid, et al.
Publicado: (2022)

Interaction between IL-6 and TNF-α genotypes associated with bacteremia in multiple myeloma patients submitted to autologous stem cell transplantation (ASCT)
por: Trigo, Fernanda M.B., et al.
Publicado: (2014)

Outcomes of Salvage Autologous Versus Allogeneic Hematopoietic Cell Transplantation for Relapsed Multiple Myeloma After Initial Autologous Hematopoietic Cell Transplantation
por: Wirk, Baldeep, et al.
Publicado: (2013)

Autologous stem cell transplant (ASCT) for AIDS-related lymphoma (ARL)
por: Krishnan, A, et al.
Publicado: (2009)

Acute Lymphoblastic Leukemia following Lenalidomide Maintenance for Multiple Myeloma: Two Cases with Unexpected Presentation and Good Prognostic Features
por: Khan, Abdullah M., et al.
Publicado: (2018)

Corrigendum to “Acute Lymphoblastic Leukemia following Lenalidomide Maintenance for Multiple Myeloma: Two Cases with Unexpected Presentation and Good Prognostic Features”
por: Khan, Abdullah M., et al.
Publicado: (2019)

A Case of Multiple Myeloma in a 17-Year-Old Girl Treated with Autologous Hematopoietic Stem Cell Transplantation (ASCT)
por: Van Man, Huynh, et al.
Publicado: (2019)

Successful autologous stem cell transplantation (ASCT) in a patient with juvenile dermatomyositis
por: Holzer, U, et al.
Publicado: (2008)

The role of ixazomib as an augmented conditioning therapy in salvage autologous stem cell transplant (ASCT) and as a post-ASCT consolidation and maintenance strategy in patients with relapsed multiple myeloma (ACCoRd [UK-MRA Myeloma XII] trial): study protocol for a Phase III randomised controlled trial
por: Striha, Alina, et al.
Publicado: (2018)

The Treatment of Multiple Myeloma Patients Not Eligible for Asct
por: Richardson, Paul, et al.
Publicado: (2010)

Feasibility and benefits of a structured prehabilitation programme prior to autologous stem cell transplantation (ASCT) in patients with myeloma; a prospective feasibility study
por: Mawson, Susan, et al.
Publicado: (2021)

Significance of maintenance therapy after HDT/ASCT in symptomatic multiple myeloma: A multicenter retrospective analysis in Kansai Myeloma Forum
por: Nakaya, Aya, et al.
Publicado: (2021)

Salvage bortezomib–dexamethasone and high-dose melphalan (HDM) and autologous stem cell support (ASCT) in myeloma patients at first relapse after HDM with ASCT. A phase-2 trial
por: Gimsing, P, et al.
Publicado: (2015)

Temozolomide followed by combined immunotherapy with GM-CSF, low-dose IL2 and IFNα in patients with metastatic melanoma
por: de Gast, G C, et al.
Publicado: (2003)

Carfilzomib and dexamethasone maintenance following salvage ASCT in multiple myeloma: A randomised phase 2 trial by the Nordic Myeloma Study Group
por: Gregersen, Henrik, et al.
Publicado: (2021)

Response to Treatment with TNFα Inhibitors in Rheumatoid Arthritis Is Associated with High Levels of GM-CSF and GM-CSF(+) T Lymphocytes
por: Bystrom, Jonas, et al.
Publicado: (2017)

Detection of Skeletal Lesions by Whole Body Multidetector Computed Tomography in Multiple Myeloma has no Impact on Long-Term Outcomes Post Autologous Hematopoietic Cell Transplantation
por: Wirk, Baldeep, et al.
Publicado: (2012)

GM-CSF in inflammation
por: Hamilton, John A.
Publicado: (2019)

PB1996: TREATMENT PATHWAYS AT FIRST RELAPSE POST-ASCT IN MULTIPLE MYELOMA: IMPACT OF MAINTENANCE THERAPY ON TREATMENT OPTIONS
por: Duane, C., et al.
Publicado: (2022)

G-CSF and GM-CSF in clinical trials.
por: Antman, K. H.
Publicado: (1990)

Ethical issues in autologous stem cell transplantation (ASCT) in advanced breast cancer: A systematic literature review
por: Droste, Sigrid, et al.
Publicado: (2011)

Immunotherapy with concurrent subcutaneous GM-CSF, low-dose IL-2 and IFN-α in patients with progressive metastatic renal cell carcinoma
por: Verra, N, et al.
Publicado: (2003)

IFN-γ-independent control of M. tuberculosis requires CD4 T cell-derived GM-CSF and activation of HIF-1α
por: Van Dis, Erik, et al.
Publicado: (2022)

GM-CSF regulates intimal cell proliferation in nascent atherosclerotic lesions
por: Zhu, Su-Ning, et al.
Publicado: (2009)

Monocytes reprogrammed with lentiviral vectors co-expressing GM-CSF, IFN-α2 and antigens for personalized immune therapy of acute leukemia pre- or post-stem cell transplantation
por: Bialek-Waldmann, Julia K., et al.
Publicado: (2019)

Recombinant GM-CSF for diseases of GM-CSF insufficiency: Correcting dysfunctional mononuclear phagocyte disorders
por: Lazarus, Hillard M., et al.
Publicado: (2023)

Maintenance Strategies Post-Autologous Stem Cell Transplantation for Newly Diagnosed Multiple Myeloma
por: Bird, Sarah A., et al.
Publicado: (2020)

Characterisation of the expression and function of the GM-CSF receptor α-chain in mice
por: Rosas, Marcela, et al.
Publicado: (2007)

IL-34 Induces the Differentiation of Human Monocytes into Immunosuppressive Macrophages. Antagonistic Effects of GM-CSF and IFNγ
por: Foucher, Etienne D., et al.
Publicado: (2013)

SOCS3 Attenuates GM-CSF/IFN-γ-Mediated Inflammation During Spontaneous Spinal Cord Regeneration
por: Zhang, Xuejie, et al.
Publicado: (2020)

Phase I Clinical Trial of Autologous Ascites-derived Exosomes Combined With GM-CSF for Colorectal Cancer
por: Dai, Shengming, et al.
Publicado: (2008)

A role for G-CSF and GM-CSF in nonmyeloid cancers
por: Aliper, Alexander M, et al.
Publicado: (2014)

Lenalidomide versus bortezomib maintenance after frontline autologous stem cell transplantation for multiple myeloma
por: Baertsch, Marc-Andrea, et al.
Publicado: (2021)

GM-CSF-Dependent Inflammatory Pathways
por: Hamilton, John A.
Publicado: (2019)

Development of Dendritic Cells from GM-CSF(-/-) Mice in vitro : GM-CSF Enhances Production and Survival of Cells
por: Ni, Keping, et al.
Publicado: (2001)

Correction: IL-34 Induces the Differentiation of Human Monocytes into Immunosuppressive Macrophages. Antagonistic Effects of GM-CSF and IFNγ
por: Foucher, Etienne D., et al.
Publicado: (2014)

Cannot write session to /tmp/vufind_sessions/sess_6l0a3tu2krv10d82cssabom5hv